Cargando…
Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123682/ https://www.ncbi.nlm.nih.gov/pubmed/35598024 http://dx.doi.org/10.1186/s13195-022-00995-9 |
| _version_ | 1784711602380996608 |
|---|---|
| author | Swanson, Chad J. Zhang, Yong Dhadda, Shobha Wang, Jinping Kaplow, June Lai, Robert Y. K. Lannfelt, Lars Bradley, Heather Rabe, Martin Koyama, Akihiko Reyderman, Larisa Berry, Donald A. Berry, Scott Gordon, Robert Kramer, Lynn D. Cummings, Jeffrey L. |
| author_facet | Swanson, Chad J. Zhang, Yong Dhadda, Shobha Wang, Jinping Kaplow, June Lai, Robert Y. K. Lannfelt, Lars Bradley, Heather Rabe, Martin Koyama, Akihiko Reyderman, Larisa Berry, Donald A. Berry, Scott Gordon, Robert Kramer, Lynn D. Cummings, Jeffrey L. |
| author_sort | Swanson, Chad J. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9123682 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-91236822022-05-22 Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody Swanson, Chad J. Zhang, Yong Dhadda, Shobha Wang, Jinping Kaplow, June Lai, Robert Y. K. Lannfelt, Lars Bradley, Heather Rabe, Martin Koyama, Akihiko Reyderman, Larisa Berry, Donald A. Berry, Scott Gordon, Robert Kramer, Lynn D. Cummings, Jeffrey L. Alzheimers Res Ther Correction BioMed Central 2022-05-21 /pmc/articles/PMC9123682/ /pubmed/35598024 http://dx.doi.org/10.1186/s13195-022-00995-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Correction Swanson, Chad J. Zhang, Yong Dhadda, Shobha Wang, Jinping Kaplow, June Lai, Robert Y. K. Lannfelt, Lars Bradley, Heather Rabe, Martin Koyama, Akihiko Reyderman, Larisa Berry, Donald A. Berry, Scott Gordon, Robert Kramer, Lynn D. Cummings, Jeffrey L. Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody |
| title | Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody |
| title_full | Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody |
| title_fullStr | Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody |
| title_full_unstemmed | Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody |
| title_short | Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody |
| title_sort | correction to: a randomized, double-blind, phase 2b proof-of-concept clinical trial in early alzheimer’s disease with lecanemab, an anti-aβ protofibril antibody |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123682/ https://www.ncbi.nlm.nih.gov/pubmed/35598024 http://dx.doi.org/10.1186/s13195-022-00995-9 |
| work_keys_str_mv | AT swansonchadj correctiontoarandomizeddoubleblindphase2bproofofconceptclinicaltrialinearlyalzheimersdiseasewithlecanemabanantiabprotofibrilantibody AT zhangyong correctiontoarandomizeddoubleblindphase2bproofofconceptclinicaltrialinearlyalzheimersdiseasewithlecanemabanantiabprotofibrilantibody AT dhaddashobha correctiontoarandomizeddoubleblindphase2bproofofconceptclinicaltrialinearlyalzheimersdiseasewithlecanemabanantiabprotofibrilantibody AT wangjinping correctiontoarandomizeddoubleblindphase2bproofofconceptclinicaltrialinearlyalzheimersdiseasewithlecanemabanantiabprotofibrilantibody AT kaplowjune correctiontoarandomizeddoubleblindphase2bproofofconceptclinicaltrialinearlyalzheimersdiseasewithlecanemabanantiabprotofibrilantibody AT lairobertyk correctiontoarandomizeddoubleblindphase2bproofofconceptclinicaltrialinearlyalzheimersdiseasewithlecanemabanantiabprotofibrilantibody AT lannfeltlars correctiontoarandomizeddoubleblindphase2bproofofconceptclinicaltrialinearlyalzheimersdiseasewithlecanemabanantiabprotofibrilantibody AT bradleyheather correctiontoarandomizeddoubleblindphase2bproofofconceptclinicaltrialinearlyalzheimersdiseasewithlecanemabanantiabprotofibrilantibody AT rabemartin correctiontoarandomizeddoubleblindphase2bproofofconceptclinicaltrialinearlyalzheimersdiseasewithlecanemabanantiabprotofibrilantibody AT koyamaakihiko correctiontoarandomizeddoubleblindphase2bproofofconceptclinicaltrialinearlyalzheimersdiseasewithlecanemabanantiabprotofibrilantibody AT reydermanlarisa correctiontoarandomizeddoubleblindphase2bproofofconceptclinicaltrialinearlyalzheimersdiseasewithlecanemabanantiabprotofibrilantibody AT berrydonalda correctiontoarandomizeddoubleblindphase2bproofofconceptclinicaltrialinearlyalzheimersdiseasewithlecanemabanantiabprotofibrilantibody AT berryscott correctiontoarandomizeddoubleblindphase2bproofofconceptclinicaltrialinearlyalzheimersdiseasewithlecanemabanantiabprotofibrilantibody AT gordonrobert correctiontoarandomizeddoubleblindphase2bproofofconceptclinicaltrialinearlyalzheimersdiseasewithlecanemabanantiabprotofibrilantibody AT kramerlynnd correctiontoarandomizeddoubleblindphase2bproofofconceptclinicaltrialinearlyalzheimersdiseasewithlecanemabanantiabprotofibrilantibody AT cummingsjeffreyl correctiontoarandomizeddoubleblindphase2bproofofconceptclinicaltrialinearlyalzheimersdiseasewithlecanemabanantiabprotofibrilantibody |